Peptide profiling of cerebrospinal fluid by mass spectrometry.
The search for biomarkers is driven by the increasing clinical importance of early diagnosis. Reliable biomarkers can also assist in directing therapy, monitoring disease activity and the efficacy of treatment. In addition, the discovery of novel biomarkers might provide clues to the pathogenesis of a disease. The dynamic range of protein concentrations in body fluids exceeds 10 orders of magnitude. These huge differences in concentrations complicate the detection of proteins with low expression levels. Since all classical biomarkers have low expression levels (e.g., prostate-specific antigen: 2-4 microg/l; and CA125: 20-35 U/ml), new developments with respect to identification and validation techniques of the low-abundance proteins are required. This review will discuss the current status of profiling cerebrospinal fluid using mass spectrometry-based techniques, and new developments in this area.
Dekker
Lennard J
LJ
Erasmus University Medical Center, Department of Neurology, PO Box 1738, 3000 DR Rotterdam, The Netherlands. l.dekker@erasmusmc.nl
Burgers
Peter C
PC
Kros
Johan M
JM
Smitt
Peter A E Sillevis
PA
Luider
Theo M
TM
D015415:Biomarkers / Q000134:cerebrospinal fluid; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D003933:Diagnosis; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D010455:Peptides / Q000134:cerebrospinal fluid*
D015415:Biomarkers; D002556:Cerebrospinal Fluid Proteins; D010455:Peptides